Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06725550 · ClinicalTrials.gov registry record · NA

Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0

A NA study of Pain and Sickle Cell Disease, sponsored by Indiana University.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT06725550 is a NA study of Pain and Sickle Cell Disease that is actively recruiting participants, run by Indiana University. The registered enrollment target is 120 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06725550, a NA study of Pain and Sickle Cell Disease, is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.

Interventions

  • DEVICE needling acupuncture
  • DEVICE laser acupuncture

Study Locations (1)

Indiana

  • Indiana University School of Medicine - Indianapolis

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-08-25
Est. Completion 2030-08-30
Phase NA

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT06725550

The ClinicalTrials.gov registry entry for NCT06725550 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (61% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which needling acupuncture is the first listed.

NCT06725550 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT06725550 about?

NCT06725550 is a clinical study titled "Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0". The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.

What is the current status of trial NCT06725550?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-08-25. Estimated completion is 2030-08-30.

What conditions does trial NCT06725550 study?

This clinical trial studies the following conditions: Pain, Sickle Cell Disease, Magnetic Resonance Imaging, Acupuncture, Electroencephalography.

What interventions are being tested in trial NCT06725550?

The interventions under investigation include: needling acupuncture (DEVICE), laser acupuncture (DEVICE).

Who is sponsoring clinical trial NCT06725550?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06725550 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.